Fighting Antibiotic Resistance

" Another example Michael courses here and so is Tim -- and Michael and and -- from a company called dot noble face therapeutics that -- threats thank you very much for coming in this is you're developing treatments from I'm told that slowdown. The onset of resistance to antibiotics. I mean how does that work I was kind of intrigued by that thing. Who okay I did not."

" That's a great question so essentially what we're doing is we can specifically. Identified. The genes that are causing antibiotic resistance to happen -- we can design new technologies that can go into the cells that are causing these. Infections as physically knock down those particular resistance change. It's -- we have a broad range of technologies or to achieve this but a lot of people do this or is anybody a student this is a pretty new approach you for go for developing these kind of therapeutics most people have been developing small molecule -- by accident are very broad spectrum. And just hit a lot of things at once we have a very targeted approach are going about this."

" And that you we all know that these things can tell it's time to actually bring to market come what is your timeline you have any -- vacation at this point is when we might see that's right so."

" We're currently in Barkley preclinical level of developments of we've gone through animal trials but you know what you're correct that it takes a long time to bring issues to the FDA's in. You know a five to seven year Thailand's kind of what we're envisioning and human Traficant known knives and --"

" You vote 52 sets of five to seven years Michael W how does that how does that play itself out in the next process from where you are now to where you're going is what might for the actual -- 57 -- time and has not taken into account the time that was spent developing and during our respective. Grad school years that's another five years. That is essentially the decree right for this and in the next five years of planning to go into initially an animal model to have a real click on -- and then say okay. A human safety trial which as you the first that phase one I think you know you -- grad school yeah I wish I could step take a step back here for a moment and -- series called -- summer right now and and tell the story of how you actually started it up. Michael you tell -- and you know insurance and as well Tim and I met at Boston University about what we're doing our -- in the -- of Jim Collins and we initially thought of working together because we're in -- in the basic science behind it how would you -- actually become. Resistant to antibiotics how to -- all of these multiple of about to happen developed over the years. And initially we were just interest and figuring out the mechanisms but as the progress towards also graduation. We figured out while the sex is something that can have an impact and for us the main the main focus is trying to bring something to the patient. In order to help them. With the situation that is getting worse and worse there are lesson lesson about the actual war while though. -- got that idea and then kind of yeah kind of ran with that. It -- it you have to be -- innovate yes I have an entrepreneurial spirit want to do this yourself Lebanese you go work for somebody else from --"

" Sure of it you know I think what really sets of the Biotech a lot of these new technologies is that we're -- an earlier -- far from the ground up. Follows on the completely new and happens to have the chance that the risk of course but have a chance -- therapeutic to the world and that's what if these -- us and our teammates and Ian. And who've been with us along the way."

" What remains of the type of this morning when I guess is how expensive it is to be innovate and I mean it's a great thing but yet very very costly and how did you get the start of."

" Money to do it again while the main thing in this economy I think and also -- to be -- so we have been doing a lot of work as as part of -- Ph.D.s that can be commercialized but. -- doing now as you some of that federal stimulus money so we're applying for grants Coca that are essentially non dilutive to we have not apportionment a couple of company. Because in this time it is progressively more difficult while I think -- it we were you have you even thought about that possibility or you -- kind of live off these grants for awhile because they have ever mostly we talked to say. Although maybe things -- started turning get better. If you had to go -- raise money that he think he could be tougher to be pretty tough and that I think Mike is right we're trying to stick with a non dilutive funding as for now we've been through a round of business plan competitions this year that we -- Actually quite a few of those who remember. Congratulations in case the sound off on and development now."

" As just because what you're doing is so revolutionary that behavior I mean I know they've been here that we."

" Talked about staph infection MRSA 25% of all staff infections are resistant to antibiotics out there so any sort of breakthrough in that would that -- I'm sure. Be very beneficial people get -- have to look at that thing Randy -- stuff like part of the equation but the from the main point is that. We can have an impact on the patients and we're not the only ones who work -- about resistant infections. But we leave the more people working at the better it is actually have somebody be able to commercial something because you're still face. With all the clinical trials are faced with FDA approval so it is a difficult road and along one it and how much do you think him in I don't know maybe this. -- you mention the impact you have amnesty think about that and say. Populate this is pretty neat that I can really this is not only -- we came up with that scientific model here we have a business. Model we're raising money we're doing that -- you could be doing that anything you can be making you know whatever cars. Planes struck us now. Have a washing machines who knows but you're doing something that impact people but how much do you think about them."

" A lot accepting about a daily basis I'm as well as directorship I'm a medical soon as well. It's on in the hospital daily seen. In patients being affected by things that. Frankly you know we should be -- we treated this right you said this could should be able to do something exactly so that's something I think about what what's going to tell you mention -- you -- a step compare it to them learn about good examples -- so I think the MRSA bacteria that your supervisor people have been worried about for a long time is definitely at the top of our list. -- there are these infections on tomatoes -- the Salmonella outbreaks music that are also very high at the top of my list as well so. There -- many different potential targets."

" We spoke to rob Armstrong earlier from Dow Jones Newswires and huge -- about having the separate flood of Biotech companies is a key game changing. Drug -- with you know the cancer under I've been talking about earlier who. Are you talking about I -- you've been looking at that is that you might be attractive to bigger pharmaceutical companies because you perhaps could be developing the game changer."

" Yeah and you know the do the key behind it is that antibiotics alone often induce resistance to happen. And so are their -- a little bit different takes complete different motive reproach and is able to actually. Reverse resistance many times so we're actually be able to push resistance back in the other direction and that's why we think -- can change."

" We're about to Kelsey -- is the is the is the goal or turn -- working for somebody else is the goal to be. Bought by somebody else is that when you think about going in or do you just let them to -- the initial the initial goal affection not to. You bought or say we want to go to the market and and then have -- I'd kill him the initial goal was let's get the technology out there so we think about it from a medical point of view from a patient impact point of view. We know that the technology can work that technology has to get out there and somebody has to push initially which is definitely us and will continue all possibilities however. We believe guilty -- go -- the technology needs to get out there not be shelved somewhere in a large company."

" And could it all ultimately also be cost saver for medical costs down the road if if people don't have to be given all these antibiotics to see which one works in the build up their resistance than they mean other than. The year drug potentially cut that down."

" a -- appointment and want to point out that we don't want to supply and antibiotics by any means we actually cool formulate our treatment with antibiotics that you have to cut some of the most of the work. And we want to also prolong the life time that they have in the clinic to have in fact these doctors be able to use. These antibiotics further felt. We hope that we can do that and we hope -- we should definitely the -- my can and can thank you for coming into the in my mind against him is what we should be looking for you guys have to after the call again have a prototype ever yes definitely a -- yeah overly critical back tomorrow that's right -- and you're gonna follow -- and look back on -- that was I left us again that's not such an -- and I should thank you thank you like you noble -- right is the name of the company. That's another example of what we've been talking about the better part of the hour that there is a lot of innovation in this in this realizes what to do quicker."